Protalix Biotherapeutics (PLX) Given a $5.00 Price Target by HC Wainwright Analysts

Protalix Biotherapeutics (NYSEAMERICAN:PLX) received a $5.00 price objective from HC Wainwright in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock.

A number of other research analysts have also issued reports on the company. Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub lowered Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd.

Protalix Biotherapeutics (NYSEAMERICAN PLX) traded up $0.03 during trading hours on Monday, reaching $0.66. The company had a trading volume of 412,713 shares, compared to its average volume of 1,060,683. The firm has a market capitalization of $319.31, a price-to-earnings ratio of -0.32 and a beta of 1.02. Protalix Biotherapeutics has a 1 year low of $0.48 and a 1 year high of $1.51.

An institutional investor recently bought a new position in Protalix Biotherapeutics stock. Opaleye Management Inc. bought a new position in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned 1.27% of Protalix Biotherapeutics as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at

Protalix Biotherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply